Clinical Trial Update: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a triple combination of tafasitamab, retifanlimab, and rituximab with standard therapy for diffuse large B-cell lymphoma a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Grade 3b Follicular Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• Retifanlimab (retifanlimab)
• Rituximab (rituximab)
• Tafasitamab (Monjuvi) (tafasitamab)

Snippet

Sponsor: University of Washington | Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1, Phase 2 | Status: RECRUITING